Compare GSK plc (GSK) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Payoneer Global Inc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Payoneer Global Inc trades at $7.14 (market cap $2.43B). The key difference: GSK plc is far larger — about 37.8× Payoneer Global Inc's market cap, and GSK plc pays a 3.9% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Payoneer Global Inc for 61 Days on average.
| GSK | PAYO | |
|---|---|---|
Market Cap | $91.88B | $2.43B |
Volume | 7,730,529 | 1,342,701 |
Sector | Health | Technology |
52-Week High | $61.18 | $7.18 |
52-Week Low | $43.24 | $4.27 |
Typical Hold Time | 93 Days | 61 Days |
Enterprise Value | $111.88B | $2.17B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Payoneer Global (PAYO) trades at $7.16 with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q2 2026 earnings of $0.02 per share, missing estimates of $0.05761, though revenue grew 10% year-over-year excluding interest. Recent developments include the renewal of its partnership with Etsy through 2029 and expansion of its India innovation hub.
The pending acquisition by Nuvei creates uncertainty, but analyst sentiment remains positive with 60% buy ratings. Key risks include integration challenges from the acquisition and competitive pressures in the fintech sector, while opportunities lie in continued B2B growth and international expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
